Literature DB >> 28319654

An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.

Li Yang1, Tessandra Stewart1, Min Shi1, Gwenael Pottiez1, Romel Dator1, Rui Wu1,2, Patrick Aro1, Robert J Schuster1, Carmen Ginghina1, Catherine Pan1, Yuqian Gao3, Weijun Qian3, Cyrus P Zabetian4,5, Shu-Ching Hu5, Joseph F Quinn6, Jing Zhang1,7.   

Abstract

AIM: The alpha-synuclein (α-syn) level in human cerebrospinal fluid (CSF), as measured by immunoassays, is promising as a Parkinson's disease (PD) biomarker. However, the levels of total α-syn are inconsistent among studies with large cohorts and different measurement platforms. Total α-syn level also does not correlate with disease severity or progression. Here, the authors developed a highly sensitive MRM method to measure absolute CSF α-syn peptide concentrations without prior enrichment or fractionation, aiming to discover new candidate biomarkers.
RESULTS: Six peptides covering 73% of protein sequence were reliably identified, and two were consistently quantified in cross-sectional and longitudinal cohorts. Absolute concentration of α-syn in human CSF was determined to be 2.1 ng/mL. A unique α-syn peptide, TVEGAGSIAAATGFVK (81-96), displayed excellent correlation with previous immunoassay results in two independent PD cohorts (p < 0.001), correlated with disease severity, and its changes significantly tracked the disease progression longitudinally.
CONCLUSIONS: An MRM assay to quantify human CSF α-syn was developed and optimized. Sixty clinical samples from cross-sectional and longitudinal PD cohorts were analyzed with this approach. Although further larger scale validation is needed, the results suggest that α-syn peptide could serve as a promising biomarker in PD diagnosis and progression.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Diagnosis; MRM; Parkinson's disease; Progression; alpha-synuclein (α-syn)

Mesh:

Substances:

Year:  2017        PMID: 28319654      PMCID: PMC5540649          DOI: 10.1002/prca.201700045

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  29 in total

1.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Authors:  Terri A Addona; Susan E Abbatiello; Birgit Schilling; Steven J Skates; D R Mani; David M Bunk; Clifford H Spiegelman; Lisa J Zimmerman; Amy-Joan L Ham; Hasmik Keshishian; Steven C Hall; Simon Allen; Ronald K Blackman; Christoph H Borchers; Charles Buck; Helene L Cardasis; Michael P Cusack; Nathan G Dodder; Bradford W Gibson; Jason M Held; Tara Hiltke; Angela Jackson; Eric B Johansen; Christopher R Kinsinger; Jing Li; Mehdi Mesri; Thomas A Neubert; Richard K Niles; Trenton C Pulsipher; David Ransohoff; Henry Rodriguez; Paul A Rudnick; Derek Smith; David L Tabb; Tony J Tegeler; Asokan M Variyath; Lorenzo J Vega-Montoto; Asa Wahlander; Sofia Waldemarson; Mu Wang; Jeffrey R Whiteaker; Lei Zhao; N Leigh Anderson; Susan J Fisher; Daniel C Liebler; Amanda G Paulovich; Fred E Regnier; Paul Tempst; Steven A Carr
Journal:  Nat Biotechnol       Date:  2009-06-28       Impact factor: 54.908

2.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.

Authors:  Tujin Shi; Thomas L Fillmore; Xuefei Sun; Rui Zhao; Athena A Schepmoes; Mahmud Hossain; Fang Xie; Si Wu; Jong-Seo Kim; Nathan Jones; Ronald J Moore; Ljiljana Pasa-Tolić; Jacob Kagan; Karin D Rodland; Tao Liu; Keqi Tang; David G Camp; Richard D Smith; Wei-Jun Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

3.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

Authors:  Takahiko Tokuda; Sultan A Salem; David Allsop; Toshiki Mizuno; Masanori Nakagawa; Mohamed M Qureshi; Joseph J Locascio; Michael G Schlossmacher; Omar M A El-Agnaf
Journal:  Biochem Biophys Res Commun       Date:  2006-08-14       Impact factor: 3.575

4.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

5.  Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Authors:  Anne M Fagan; Leslie M Shaw; Chengjie Xiong; Hugo Vanderstichele; Mark A Mintun; John Q Trojanowski; Els Coart; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2011-05-09

6.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Authors:  Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

Review 7.  Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.

Authors:  Steffen Halbgebauer; Patrick Öckl; Katharina Wirth; Petra Steinacker; Markus Otto
Journal:  Mov Disord       Date:  2016-05-02       Impact factor: 10.338

8.  Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain.

Authors:  J Zhang; C A Piantadosi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Authors:  Sara Hall; Annika Öhrfelt; Radu Constantinescu; Ulf Andreasson; Yulia Surova; Frederick Bostrom; Christer Nilsson; Widner Håkan; Hilde Decraemer; Katarina Någga; Lennart Minthon; Elisabet Londos; Eugeen Vanmechelen; Björn Holmberg; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  Arch Neurol       Date:  2012-11

10.  Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome.

Authors:  Zbyšek Pavelek; Oldřich Vyšata; Vojtěch Tambor; Kristýna Pimková; Dai Long Vu; Kamil Kuča; Pavel Šťourač; Martin Vališ
Journal:  Biomed Rep       Date:  2016-04-28
View more
  4 in total

Review 1.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

Review 2.  Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.

Authors:  Rita Azevedo; Chloé Jacquemin; Nicolas Villain; François Fenaille; Foudil Lamari; François Becher
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

Review 3.  Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson's Disease.

Authors:  Marie-Laure Pons; Neil Loftus; Jerome Vialaret; Stephane Moreau; Sylvain Lehmann; Christophe Hirtz
Journal:  Front Aging Neurosci       Date:  2022-03-31       Impact factor: 5.750

Review 4.  Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson's Disease.

Authors:  Rekha Raghunathan; Kathleen Turajane; Li Chin Wong
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.